Kreuzstrasse 2, 4123 Allschwil, Switzerland
+ 41 (0)61 284 81 11, www.swisstph.ch
Swiss TPH presents an ordinary result of CHF – 125,647 in 2022, compared to CHF +3,261,026 in 2021. The operating result from activities amounts to CHF – 346,284, which represents a decrease of CHF 880,935 in comparison to 2021 (CHF +534,651). This result was achieved despite a challenging environment with a strong Swiss Franc, increases in energy costs and growing operating expenses of our new headquarters “Belo Horizonte”.
The financial result reached CHF +220,636 (compared to CHF +172,378 in 2021), mainly due to on favourable exchange rate transactions and unrealised gains on foreign currency holdings in USD/CHF and EUR/CHF. This is one of the active risk mitigation measures taken by Swiss TPH management in order to reduce currency exposure.
In 2022, Swiss TPH reports no extraordinary result. In 2021 an extraordinary gain of CHF +2,553,997 resulting from the sale of the property at Socinstrasse in Basel was realised.
The operating income of Swiss TPH increased (+10.9%) from CHF 94.5 million in 2021 to CHF 104.8 million in 2022. Excluding the effect on the income statement from the utilisation of the “Belo Horizonte” investment fund (CHF 2.1 million), sales growth would have been as high as CHF 8.2 million or 8.7% in nominal terms in 2022, as compared to 2021.
The core funding increased slightly from CHF 21.3 million in 2021 to CHF 22.7 million in 2022 (+6.7%). The project restricted funds from the State Secretariat for Education, Research and Innovation (SERI) has been reclassified from core funding to self-managed income. Previous year disclosure has been updated accordingly to ensure comparability of the figures.
In 2022, Swiss TPH managed to increase its share of competitively acquired third-party funding. Self-managed income from research, education and services increased to CHF 78.5 million in 2022, representing a growth of CHF 10.2 million or 14.9% compared to the previous year (CHF 68.3 million).
Personnel expenses increased by 4.7% or CHF 2.6 million from CHF 55.2 million in 2021 to CHF 57.8 million in 2022. The growth was mainly driven by higher salary costs (+CHF 1.2 million) with 14 additional employees on the payroll. Furthermore, an increase in travel expenses due to rising travel activities and costs (+CHF 1.1 million) was registered.
Other operating expenses increased by 20.5% or CHF 5.9 million from CHF 28.6 million in 2021 to CHF 34.5 million in 2022. With an increase of CHF 2.4 million, local project expenditures contributed substantially to the rise and are the consequences of enhanced project activities. Furthermore, an increase of 3.4 million in renting, energy and maintenance expenditures mainly contributed to the rise in other operating expenses. The majority of local project expenditures, totalling CHF 27.4 million in 2022 versus CHF 25.0 million in 2021, were spent in Africa (CHF 16.2 million, an increase of CHF 0.5 million). The local expenditures for European projects rose by CHF 2.4 million to CHF 10.4 million.
The depreciation costs amounted to CHF 3.3 million in 2022 (CHF +1.8 million) compared to 2021. This rise was mainly driven by the completion of the investments for the new headquarters “Belo Horizonte” in 2022. The depreciation costs contain CHF 2.1 million, which were covered by the utilisation of the investment fund “Belo Horizonte” recognised within other operating income.
Balance Sheet
Total assets decreased by 20.6% (CHF 18.4 million) to CHF 70.9 million compared to 2021.
Current assets decreased by 25.6% or CHF 18.6 million yearon-year to CHF 54.2 million in 2022 from CHF 72.8 million in 2021. Therein cash and cash equivalents decreased by CHF 5.4 million or 14.8% from CHF 36.2 million in 2021 to CHF 30.8 million in 2022. The reason was the remaining purchase of fixed assets for Swiss TPH, which were capitalized in 2022 and the reduction of payables.
Other short-term receivables decreased by CHF 2.3 million or 21.0% to CHF 8.7 million in 2022 compared to the previous year due to the decreased number of advances for projects to be implemented locally or for subcontractors within project assignments.
Swiss TPH also noted a decrease in prepayments and accrued income from 2021 to 2022. The decline amounted to CHF 3.7 million or 33.5% and is due to decreased advance payments for projects on behalf of Swiss TPH.
Non-current assets increased slightly by CHF 0.2 million to CHF 16.8 million in 2022 compared to 2021. The categories “Building” and “Equipment” increased by CHF 11.9 million mainly due to the reclassification of assets under construction, which decreased sharply by CHF 14.9 million. The assets under construction reclassified in 2022 mainly consist of laboratory equipment, furniture, IT-equipment and other fixtures and fittings in the new headquarters.
Current liabilities declined sharply to CHF 49.7 million in 2022 compared to CHF 67.4 million in 2021 as a result of active cash management by reducing payables to prevent negative interest on bank accounts. In this regard, payables from goods and services decreased from CHF 10.6 million in 2021 to CHF 3.1 million in 2022. Other payables decreased from CHF 5.5 million in 2021 to CHF 2.0 million in 2022.
Accrued liabilities and deferred income decreased from CHF 48.7 million in 2021 to CHF 42.2 million in 2022.
Non-current liabilities decreased slightly from CHF 13.4 million in 2021 to CHF 12.8 million in 2022.
As a result of the 2022 loss of CHF 125,647, equity decreased from CHF 8,544,462 (31 December 2021) to CHF 8,418,815 (31 December 2022).
*2021: 1,750K reclassified under position self-managed income (restricted funds)
The Swiss Tropical and Public Health Institute (Swiss TPH) announces a loss of CHF – 125,647 for the year 2022, in contrast to a gain of CHF 3,261,026 in 2021, which included an extraordinary gain resulting from the sale of the property at Socinstrasse in Basel.
Hence, the equity slightly decreased to CHF 8,418,815 in 2022 compared to CHF 8,544,462 in 2021. Nonetheless, the equity ratio could be increased to 11.9% in 2022 compared to 9.6% in 2021 due to reduction of the balance sheet total as of 31 December 2022.
The Swiss Tropical and Public Health Institute (Swiss TPH) is a public organisation based in Allschwil with its own legal status under the laws of Switzerland (“öffentlich-rechtliche Anstalt”).
By uniquely combining research, education and services, Swiss TPH aims to improve the health and well-being of populations through a better understanding of disease and health systems and by acting on this knowledge. Our translational approach, from innovation and validation to application, enables us to bring novel diagnostics, drugs and vaccines directly to people and communities. On 1 January 2017, the treaty between the Canton Basel-Stadt and the Canton Basel-Landschaft concerning the common ownership of the Swiss TPH came into force.
The Board of Governors is called the “Kuratorium”. Four members each are appointed by the Governments of the Canton of Basel-Stadt and the Canton of Basel-Landschaft, whereas the President is appointed by both Governments
As of 31 December 2022, the composition of the Kuratorium was as follows:
Dr. Andreas Burckhardt (until 31.12.2022)
President
Dr. Eva Herzog (as of 01.01.2023) President
Dr. Rolf Borner
Dr. Ariane Bürgin
Prof. Dr. François Chappuis
Prof. Dr. Sabina De Geest
Dr. Olivier Küttel
Dr. Cornelia Staehelin
Dr. Benedikt Knüsel (until 31.08.2022, Observer SERI)
Dr. Luca Tratschin (as of 01.12.2022, Observer SERI)
The Committee monitors the financial and accounting processes and systems of Swiss TPH, evaluates the independence and effectiveness of the external auditors and ensures the flow of communication between the Directorate, the Administration, Auditor, and the Board of Governors (“Kuratorium”). The Committee makes appropriate recommendations to the Kuratorium.
The actual members are:
Dr. Eva Herzog (as of 01.01.2023) President
Dr. Rolf Borner
Dr. Ariane Bürgin
Dr. Alban Frei (as of 01.02.2023)
PricewaterhouseCoopers AG, Basel has been assigned by the Governments of the Cantons BaselStadt and Basel-Landschaft as the auditor of Swiss TPH.
These financial statements have been prepared in accordance with Swiss GAAP FER, issued by the foundation for accounting and reporting recommendation, Switzerland.
Swiss TPH presentation currency is CHF (Swiss francs).
Assets and liabilities in foreign currency are valuated at the exchange rate provided by the federal tax administration at the balance sheet date. Foreign currency transactions are recorded on initial recognition in the functional currency at the transaction rate. Exchange rate differences are recognised in the income statement.
Revenues from rendering medical services and fees from education and training are recognised in the period of providing those services. Revenues from projects are recognised to the extent of the recoverable expenses of the reporting period. Project results are neutralised during the project period, an eventual result is realised at the end of the project. Funds from national and local government are recognised in the period for which they were funded.
All borrowing costs are recognised in the income statement in the period in which they are incurred.
Core tangible fixed asset items are measured at cost less accumulated depreciation and any accumulated impairment losses.
Depreciation is charged so as to allocate the cost of assets less their residual values over their estimated lifetime, using the straight-line method. The following annual rates are used for depreciation of property, plant and equipment.
The capitalisation of maintenance costs depends on whether they are value-preserving or value-adding, respectively extending the useful life of the respective fixed asset. Whenever there is an indication that there has been a significant change in depreciation rate, useful life or residual value of an asset, the deprecation of that asset is revised prospectively to reflect the new expectations.
Employer contribution reserves or similar items are recognised as assets under long-term financial assets. The difference to the respective value of the prior year is recognised as personnel expenses in the result of the period.
Intangible assets are purchased computer software that is measured at cost less accumulated amortisation and any accumulated impairment losses. Software is amortised over its estimated useful life time of 4 years using the straight-line method.
Inventories are valued at the lower of cost and selling price. Cost is calculated using the average-method.
At each reporting date, fixed and intangible assets are reviewed to determine whether they have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. If the estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount. An impairment loss is recognised immediately in the income statement.
Fixed assets at costs less than CHF 5,000 are not capitalised.
Fixed assets purchased with project funds for the purpose of project operations are not capitalised as the ownership of these assets remains with the donor.
Similarly, at each reporting date, inventories are assessed for impairment by comparing the carrying account of each inventory item with its selling price less costs to complete and sell. If an item of inventory is impaired, an impairment loss is recognised immediately in the income statement.
If an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been
recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in the income statement.
An impairment in receivables is recognised if the carrying amount of the assets is less than the present value of the expected future cash flow. The provision for bad debts is calculated by categorising the debts as follows:
Payables are recorded at their fair value, represented by the amount to pay.
Provisions are determined based on impartial and economically reasonable principals. Risks are taken into account adequately.
The procurement of remaining fixed assets for the new headquarters “Belo Horizonte” in Allschwil was completed and the investment capitalized in 2022. These assets are now reclassified from assets under construction to different asset categories (table 4.7).
In addition, the reduction of payables as part of the active liquidity management to prevent unnecessary negative interest on bank accounts resulted in a significant cash outflow of CHF 5.4 million.
The open positions of receivables from services as per 31.12.2022 has been reduced by an effective dunning process and systematic management of receivables.
Payments up to 07 February 2023 are included in the calculation.
Swiss TPH recorded a decrease in prepayments and accrued income from 2021 to 2022. The reduction amounted to CHF 3.7 million or 33.5% and is due to lower advance payments in pro -
jects on the part of Swiss TPH. This is also the result of active liquidity management to prevent unnecessary negative interest on bank accounts.
The assets under construction have been completed and reclassified to their respective asset categories in the year 2022.
As a result the annual depreciation costs of CHF 3.6 million in 2022 doubled compared to 2021.
CHF 2.1 million of the annual depreciation costs (CHF 3.6 million) are covered by the utilisation of the investment fund “Belo Horizonte” recorded within other operating income.
Investments > CHF 5,000 with project funds (not capitalised)
The ownership of investments paid with project funds generally remains with the donor. Therefore, these investments are not capitalised but
recorded in the fixed assets register and disclosed below:
-
Assets under construction with the substantial amount of CHF 14.9 million were reclassified to the corresponding asset categories in 2022 (table
4.7). These are mainly furniture, laboratory equipment, IT-equipment and other fixtures and fittings in the new headquarters in Allschwil.
There is no existing mortgage in 2022 as Swiss TPH does not own any building.
Based on the accounts at the end of the year, the project leaders evaluated the accrued revenues and expenses (cost to complete) for their projects. These evaluations were taken into consideration by the Directorate on the occasion of the approval
of the financial statements. All of the project related deferred income is sustained based on existing project contracts. At the moment, there is no indication for any losses from long-term projects, which would need to be recognised.
Remaining provisions
Not compensated vacation: The provision for employee vacation credits was re-evaluated
Advances: Advances granted to a partner institution for which a significant recovery exists were re-evaluated
Court cases: Risk on existing/ongoing court cases were re-evaluated
Research Fund: The research provision was increased by CHF 53,073 due to the internal regulations for the Research Fund.
Insolvency Tajik Bank: Loss of CHF 60,000 as the bankrupt bank will not repay the balance on our account.
The total overhead contribution of the Swiss National Science Foundation (SNSF) is paid in the year
of grant allocation. The provision allows the use of the contribution during the whole project period.
Changes of provisions and deferred
According to the decision made at the Directorate’s meeting (17 – 19 October 2006), a provision of CHF 500,000 for personnel or their dependants in case of hardship was created. The disposition of fund means is defined in the fund regulations.
The provision for potential taxes abroad is created for those countries where expatriates or local Swiss TPH staff are possibly supposed to pay income taxes.
According to local labour law in various project countries, such as the Democratic Republic of the Congo, Tanzania, Albania and Rwanda, end of contract payments are to be borne by the employer.
Swiss TPH committed to cover CHF 10,000,000 of the investments costs of the new headquarters “Belo Horizonte”. For this purpose, this amount was accrued in the period of 2017 – 2020. In 2022 the Investment Fund has been increased to the total amount of CHF 11,216,798 by the contribution of CHF 1,216,798 through the R. Geigy Foundation. Of the annual depreciation costs an amount of CHF 2,104,307 related to investments covered by the Investment Fund, and hence, was released. This resulted in a net release of CHF 887,508 during 2022 and the closing balance of CHF 9,112,492.
* CHF 44,381 included under position of Research
Swiss TPH managed to increase its share of competitive third-party funding. Self-managed income from research, education and services
increased to CHF 78.5 million in 2022, representing a growth of CHF 10.2 million or 14.9% compared to the previous year (CHF 68.3 million).
In addition to the income generated competitively through research and services, Swiss TPH receives funding from the local and the national
government as well as from the University of Basel:
*reclassification into table 4.15: earmarked SERI funds restricted for projects
Contributions within “University of Basel” include “SNF overhead” and “Unibas matching funds” for 2019. These revenues are project-specific and are no longer included in the core contributions
Within the scope of the inter-cantonal contract concerning the common ownership of the University of Basel between the cantons of BaselStadt and Basel-Landschaft, Swiss TPH was granted a contribution of CHF 6,608,000 (2021: CHF 6,040,000) for the period of 2022 for struc-
tural professorships and teaching activities within the curriculum of the University of Basel.
Based on the new performance agreement between the University of Basel and the Swiss TPH (in force as of 1 January 2022), the following subsidies have been agreed from 2022 onwards.
Based on the performance mandate of the governments of the cantons of Basel-Stadt and Basel-Landschaft to the Swiss TPH for the years
2021 – 2024, the following contributions of the cantons were granted.
Based on the “decree regarding the application of Swiss TPH of 30 June 2019 for a federal contribution according to Art. 15 of the Federal Law
on the Promotion of Research and Innovation (FIFG) for the years 2021 – 2024”, the following contributions were approved:
The amount defined in the service agreement and the decree for 2022 was reduced by the federal government by 0.3% to 8,100,900. Reductions might also occur for the following years within the framework of the debt brake.
As a founding member of the Centre Suisse de Recherches Scientifiques en Côte d’Ivoire (CSRS)
and the Ifakara Health Institute (IHI) in Tanzania, Swiss TPH acts as the leading house on behalf of SERI and administers the following funds based on the performance agreement for the years 2021 – 2024.
Based on the performance agreement for the years 2021 – 2024, the following contributions were granted for international cooperation with foreign partners.
Other operating income is income which is not related directly to grant and project contracts such as royalties, consultancies, cafeteria, reimbursed travel cost, etc.
Personnel expenses increased by 4.7% or CHF 2.6 million from CHF 55.2 million in 2021 to CHF 57.8 million in 2022, mainly driven by higher salary costs (+CHF 1.2 million), explained by 14 additional employees on the payroll. Furthermore, an increase in travel expenses due to rising travel
Pension funds
Swiss TPH’s pension plan is a pension scheme according to the federal law on occupational pension schemes (BVG) and is part of the “Helvetia Sammelstiftung für Personalvorsorge”, contract number 30935. The funding consists of employers’ contributions, employees’ contributions and
activities (+CHF 1.1 million) which reached the level before the COVID– 19 pandemics.
All expenses and costs are recognised in the income statement. In respect of accruals for overtime and vacation please refer to note 4.11 and 4.12.
of an annual interest (1% since 1 January 2017). This pension plan is part of a collective plan with reinsurance arrangements (full insurance within the framework of a collective insurance contract), the Swiss TPH is not the risk bearer and therefore no additional payment obligations can arise in case of a deficit.
No compensation is paid to the Board of Governors. Only defined trip allowances and boarding costs are paid.
Expenses to the Directorate are paid according to the Manual for Employees.
> CHF 5,000 with project funds
The increase of material expenses from 2.7 million in 2021 to 4.0 million in 2022 is primarily due to the rising project activities in 2022.
Informatics contains procurement for IT-equipment <CHF 5,000.
Other operating expenses increased by 20.5% or CHF 5.9 million from CHF 28.6 million in 2021 to CHF 34.5 million in 2022. Thereof, CHF 2.4 million relate to local project expenditures and are the consequences of the renewed increase in
project activities. Furthermore, an increase of 3.4 million in renting, energy and maintenance expenditures mainly contributed to the rise in other operating expenses.
Project expenditures abroad by donors
Please note: A donor is listed if more than CHF 40,000 is expensed in 2022.
The main local expenditures were incurred in the following countries, which include the expenditures of Swiss TPH projects and local offices abroad: Albania, Benin, Burkina Faso, Burundi, Cameroon, Côte d’Ivoire, Chad, Democratic Republic of the Congo, Gambia, Guinea, Liberia, Mali, Moldova, Niger, Rwanda, Senegal, Tanzania and Ukraine.
Most of the local project expenditures, totalling CHF 27.4 million in 2022 versus CHF 25.0 million in 2021, were spent in Africa (CHF 16.2 million, an increase of CHF 0.5 million). The local expenditures for European projects rose by CHF 2.4 million to CHF 10.4 million.
The financial result reached CHF +220,636 (CHF +172,378 in 2021), which was primarily based on favourable exchange rate transactions and un-
realised gains on foreign currency holdings in USD/CHF and EUR/CHF.
In 2022, Swiss TPH reports no extraordinary result. In 2021 an extraordinary gain of CHF +2,553,997
Total off-balance sheet leasing liabilities which cannot be withdrawn or expire within the next 12 months:
The purpose of the R. Geigy Foundation is to support Swiss TPH in different projects. The following list shows the granting of funds:
resulting from the sale of the property at Socinstrasse in Basel was realised.
Swiss TPH actively manages its risks related to the financial statement. A yearly risk assessment considers the probability of occurrence and the severity of damages of the identified risks and appropriate measures are defined. The risk assessment is performed by the Directorate and then subsequently reviewed and approved by the Board of Governors.
These financial statements were prepared and approved by the management of Swiss TPH as representatives of the Board of Directors. They are subject to final approval by the Board of Governors (Kuratorium) on 17 May 2023.
Core Funding
Canton Basel-Landschaft, CH
Canton Basel-Stadt, CH
State Secretariat for Education, Research and Innovation (SERI), CH
University of Basel, CH
Research Funding
Botnar Research Centre for Child Health (BRCCH), CH
EU research grants (e.g. ERC, Horizon, EDCTP), EU National Institutes of Health (NIH), US
Swiss National Science Foundation (SNSF), CH University of Basel, CH
Foundations
Aeras Global TB Vaccine Foundation, US
Albert-Heim-Stiftung, CH
Anesvad, ES
Baylor College of Medicine Children’s Foundation Lesotho (BCMCFL), LS
Bill & Melinda Gates Foundation (BMGF), US
Biovision, CH
Boehringer Ingelheim Fonds, DE
CDC Foundation, US
Cesti Fondatione Onlus, IT
Clinton Health Access Initiative (CHAI), US
Computer Simulation & Advanced Research Technologies (CSART), AU
Eckenstein-Geigy-Stiftung, CH
Elrha, GB
Else Kröner-Fresenius-Stiftung (EKFS), DE
Fondation Botnar, CH
Fondazione Adiuvare, CH
Fondazione lstituto Nazionale di Genetica Molecolare (INGM), IT
Freiwillige Akademische Gesellschaft (FAG), CH
Global Health Innovative Technology Fund (GHIT), JP
Health Information Traceability Foundation (HIT), CH
Krebsforschung Schweiz, CH
Moritz Straus-Stiftung, CH
Novartis Foundation, CH
R. Geigy Foundation, CH
Sight and Life (SAL), CH
Sint Antonius Foundation, NL
Skat Foundation, CH
Stanley Thomas Johnson Foundation, CH
Swiss Network for International Studies (SNIS), CH
Syngenta Foundation for Sustainable Agriculture (SFSA), CH
Walter Fischli Stiftung, CH
Wellcome Trust, GB
Public Clients Switzerland
Amt für Ausbildungsbeiträge Basel-Stadt, CH
Amt für Umwelt und Energie Basel-Stadt, CH
Bundesamt für Raumentwicklung (ARE), CH
Commission for Research Partnerships with Developing Countries (KFPE), CH
Entwicklungszusammenarbeit des Kantons Basel-Stadt, CH
Federal Department of Defence, Civil Protection and Sport (DDPS), CH
Federal Department of Economic Affairs, Education and Research (EAER), CH
Federal Food Safety and Veterinary Office (FSV), CH
Federal Office of Public Health (FOPH), CH
Federal Office of Sport (FOSPO), CH
Federal Office of the Environment (FOEN), CH
Federal Statistic Office (BFS), CH
Gesundheitsförderung Schweiz, CH
Innosuisse - Swiss Innovation Agency, CH
Kantonsspital Basel-Landschaft, CH
MeteoSchweiz, CH
Nationales Referenzzentrum für Legionellen (NRZL), CH
Swiss Agency for Development and Cooperation (SDC), CH
Swiss Federal Institute of Aquatic Science and Technology (Eawag), CH
Swiss Federal Laboratories for Materials Science and Technology (EMPA), CH
Swiss Pathogen Surveillance Platform (SPSP), CH
Swiss Personalized Health Network (SPHN), CH
University Hospital Basel, CH
Public and Public-Private Clients International
African Population and Health Research Center (APHRC), KE
African Society for Laboratory Medicine (ASLM), ET
Agence Française de Développement (AFD), FR
Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES), FR
Asian Development Bank (ADB), PH
Association of Churchbased Development NGOs (ACDEP), GH
Bundesamt für Auswärtige Angelegenheiten (BfAA), CH
Canadian Association for Global Health (CAGH), CA
Centers for Disease Control and Prevention (CDC), US
Centre de Support en Santé Internationale (CSSI), TD
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ), DE Direction des Services Vétérinaires (DSV), FR
Drugs for Neglected Diseases initiative (DNDi), CH
Elgo Dimitra - Ellinikos Georgikos Organismos, GR Epicentre, FR
European Institute of Public Health Policy (EIPHP), UA
Food and Drug Administration (FDA), US Foundation for Innovative New Diagnostics (FIND), CH
Gavi, the Vaccine Alliance, CH
German Institute for Medical Mission (DIFAM), DE Global Fund to Fight AIDS, Tuberculosis and Malaria, CH
Grand Challenges Canada, CA
Health and Environment Alliance (HEAL), BE
Helse Nord Tuberculosis Initiative Malawi (HNTI), NO
Human Sciences Research Council (HSRC), ZA
Innovations for Poverty Action (IPA), US Institut de Recherche pour le Développement (IRD), FR Institut de Recherches en Elevage pour le Développement (IRED), TD Institut National d’Hygiène Publique (INHP), CI Institut national de l'environnement industriel et des risques (Ineris), FR Instituto Nacional de Saúde (INS), MZ
International Committee of the Red Cross (ICRC), CH
ISGlobal, ES
Kreditanstalt für Wiederaufbau (KfW), DE Medical Care Development International (MCDI), US
Medicines for Malaria Venture (MMV), CH
Muséum national d’Histoire naturelle, FR National Center of Tuberculosis and Lung Diseases (NCTLD), GE
National Public Health Center (Nemzeti Népegészségügyi Központ), HU
Norwegian Agency of Development Cooperation (Norad), NO
Nutrition International, CA
Organisation de Coordination pour la lutte contre les endémies en Afrique Centrale, CM
Right to Care Zambia (RTCZ), ZM
Schistosomiasis Control Initiative Foundation (SCI), GB
Swiss Red Cross (SRC), CH
The International Society for Research in Human Milk and Lactation (ISRHML), US tropEd Network for Education in International Health, DE
Unitaid, CH
United Kingdom Department for International Development (DFID), GB
United Nations Children Fund International (Unicef), US
United Nations Development Programme (UNDP), US
United Nations Population Fund (UNFPA), US
United States Agency for International Development (USAID), US
West African Health Organisation (WAHO)
World Bank, US
World Health Organization (WHO), CH
World Organisation for Animal Health (WOAH), FR
Private Clients and Non-Profit Organisations
AEDES, BE
Anglo American Services (UK) Ltd., GB
Astellas Pharma AG, CH
Bacoba AG, CH
BASF SE, DE
Bayer AG, CH
BioInitials, CH
Bristol Myers Squibb, US
Cardno Emerging Markets East Africa Ltd. (CEM), KE
Conseil Santé, FR
Effectum Medical AG, CH
Fields at Work GmbH, CH
Game Solutions Lab, NL
GFA Consulting Group GmbH, DE
Grolimund + Partner AG, CH
Health Effects Institute (HEI), US
Hemex AG, BS
Ideas for Change, ES
Insuco, UK
International Association for Maternal and Neonatal Health (IAMANEH), CH
Life4me+, CH
Lygature, NL
Martin Systems GmbH, DE
Médecins Sans Frontières (MSF), CH
Merck, DE
NED-TECH AG, CH
Novartis Pharma AG, CH
OmicScouts, DE
OptiMedis AG, DE
Oryx Expertise, FR
Pact, US
PATH, US
Privatklinik Meiringen, CH
RANAS Ltd., CH
Rotarians Against Malaria (RAM), PG
Science for Change, ES
Seboche Mission Hospital, LS
SKAN, CH
SolDevelo, PL
SolidarMed, CH
Specs Compound Handling B.V., NL
Swiss Excellence Forum, CH
Syngenta, CH
Terre des hommes, CH
Universitätsklinikum Bonn (UKB), DE
VisibleSolutions AG, CH
Wits Health Consortium (Pty) Limited (WHC), ZA
Academic Partners
Academic Medical Center (Academisch Medisch Centrum), NL
Addis Ababa University (AAU), ET
Agricultural University of Athens, GR
Armauer Hansen Research Institute (AHRI), ET Berner Fachhochschule (BFH), CH
Bernhard-Nocht-Institut für Tropenmedizin, DE Boston University, US
Brown University, US
Centre hospitalier régional et universitaire de Besançon (CHRU), FR
Centre national de la recherche scientifique (CNRS), FR
Centre Suisse d’Electronique et de Microtechnique (CSEM), CH
Centre Suisse de Recherches Scientifiques en Côte d’Ivoire (CSRS), CI
Charité – Universitätsmedizin Berlin, DE
College of Art and Sciences, Xavier University, Cincinnati, US
Consiglio Nazionale delle Ricerche, IT
Cyprus University of Technology, CY
École Polytechnique Fédérale de Lausanne (EPFL), CH
Eindhoven University of Technology, NL
Eucor – The European Campus, CH, DE, FR
Forschungszentrum Borstel, Leibniz Lungenzentrum (FZB), DE
Geneva University Hospitals (HUG), CH
Ghent University, BE
Harvard T.H. Chan School of Public Health, US
Helmholtz Centre for Infection Research, DE
Ifakara Health Institute (IHI), TZ
Innovative Vector Control Consortium (IVCC), GB
Inselspital Bern, CH
Institut Mines-Télécom (IMT), FR
Institut Pasteur, FR
Institute of Social and Preventive Medicine (ISPM), Bern, CJ
Institute of Tropical Medicine Antwerp (ITM), BE
Instituto de Higiene e Medicina Tropical Universidade Nova de Lisboa (IHMT), PT Instituto Nacional de Saúde (INS), MZ
Institutul de Ftiziopneumologie “Chiril Draganiuc”, MD
Institutul de Pneumoftiziologie “Marius Nasta” (IPMN), RO
James Cook University (JCU), AU
KEMRI - Wellcome Trust Research Programme, KE
Kenya Medical Research Institute (KEMRI), KE
Lao Tropical and Public Health Institute (Lao TPHI), LA
Lausanne University Hospital (CHUV), CH
Liverpool School of Tropical Medicine (LSTM), GB
London School of Hygiene & Tropical Medicine (LSHTM), GB
Lucerne University of Applied Sciences and Arts (HSLU), CH
Ludwig Maximilian University of Munich (LMU), DE
Makerere University, UG
Manhiça Health Research Centre (CISM), MZ
Massachusetts General Hospital, US
Moi University, KE
MRC/Wits Agincourt Field Office, ZA
National Institute for Medical Research (NIMR), TZ
National Institute for Research in Tuberculosis (ICMR), IN
National Institute of Health (NIH), US
Nofer Institute of Occupational Medicine, PL
Norwegian University of Life Sciences (NMBU), NO
Obafemi Awolowo University, NG
Ospedale San Raffaele (SRL), IT
Palestine Polytechnic University, PS
Papua New Guinea Institute of Medical Research (PNG IMR), PG
Paul Scherrer Institute, CH
Penta Child Health Research, IT
PNG National Research Institute, PG
Public Health Laboratory Ivo de Carneri (PHL-IdC), TZ
Qom University of Medical Sciences, IR
Radboud University Nijmegen, NL
Rwanda Biomedical Centre (RBC)
Sapienza University of Rome, IT
School of Social Work Fribourg (HETS-FR), CH
South African Medical Research Council, ZA
Swiss Association for Quality (SAQ), CH
Swiss Federal Institute of Technology in Zurich (ETHZ), CH
Swiss Institute of Bioinformatics (SIB), CH
Swiss School of Public Health (SSPH+), CH
swissuniversities Development and Cooperation Network (SUDAC), CH
Technische Universität München (TUM), DE
Temple University, US
The Aurum Institute, ZA
The George Institute for Global Health India, IN
Umeå University, SE
Unisanté, CH
Universidad Peruana Cayetano Heredia (UPCH), PE
Universität St. Gallen, CH
Universitäts-Kinderspital beider Basel (UKBB), CH
Université de Genève, CH
Université de Lausanne, CH
Université de Neuchâtel, CH
Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), ML
Université Félix Houphouët-Boigny (UFHB), CI
University of Antwerp, BE
University of Applied Sciences and Arts Northwest Switzerland (FHNW), CH
University of Applied Sciences and Arts of Southern Switzerland (SUPSI), CH
University of Applied Sciences and Arts Western Switzerland (HES-SO), CH
University of Basel, CH
University of Bergen (UiB), NO
University of Bern, CH
University of Bologna, IT
University of Buea, CM
University of Calabar, NG
University of California San Francisco (UCSF), US
University of Cambridge, GB
University of Cape Town, ZAUniversity of California, San Francisco (UCSF), US
University of Dundee, GB
University of Ghana, GH
University of Ghent, BE
University of Gothenburg, SE
University of Groningen (RUG), NL
University of Health and Allied Sciences (UHAS), GH
University of Heidelberg, DE
University of Ibadan (UI)
University of KwaZulu-Natal
University of Lugano, CH
University of Luzern, CH
University of Maiduguri, NG
University of Malawi, MW
University of Maryland, US
University of Montpellier, FR
University of Nebraska, US
University of Oxford, UK
University of Pécs, HU
University of Sao Paulo (USP), BR
University of Strasbourg, FR
University of the Witwatersrand, ZA
University of Turin, IT
University of Utrecht, NL
University of Vienna, AU
University of Warwick, GB
University of Washington (UW), US
University of Zurich, CH
Weizmann Institute of Science, IL Yale University, US
*The list reflects all Swiss TPH partners and funders that are within our staffmanaged project database.
